Development of Vascular Substitutes

1998 ◽  
Vol 550 ◽  
Author(s):  
Robert M. Nerem

AbstractA long-term objective of many involved in blood vessel research is the development of a small diameter vascular substitute which can be used in coronary bypass graft surgery. If these efforts are to be successful, there are critical functional characteristics which must be achieved. In recent years many of those interested have turned their attention to tissue engineering, and over the past decade some progress has been reported. The results of some of these efforts are briefly reviewed here. Included is the strategy of the Georgia Tech team and recent results which demonstrate that in vitro mechanical stimulation of smooth muscle cell-seeded tubular collagen constructs induces a remodeling with the result that the associated material properties are considerably enhanced.

1996 ◽  
Vol 131 (4) ◽  
pp. 836-839
Author(s):  
William G. Kussmaul ◽  
Francis C. Kempf ◽  
Kenneth L. Kershbaum

2005 ◽  
Vol 79 (2) ◽  
pp. 532-536 ◽  
Author(s):  
Lawrence J. Dacey ◽  
Donald S. Likosky ◽  
Bruce J. Leavitt ◽  
Stephen J. Lahey ◽  
Reed D. Quinn ◽  
...  

1991 ◽  
Vol 17 (5) ◽  
pp. 1075-1080 ◽  
Author(s):  
Gerald M. FitzGibbon ◽  
Alan J. Leach ◽  
Henryk P. Kafka ◽  
Wilbert J. Keon

1995 ◽  
Vol 89 (5) ◽  
pp. 481-485 ◽  
Author(s):  
James J. Liu ◽  
Joan R. Chen ◽  
Brian B. Buxton ◽  
Colin I. Johnston ◽  
Louise M. Burrell

1. The effect of vasopressin receptor antagonists varies between analogues (peptide, non-peptide) and across species. In this study the effect of the novel non-peptide vasopressin V1a receptor antagonist SR 49059 on human internal mammary arteries was investigated. 2. SR 49059 produced a potent, concentration-dependent, inhibitory effect on vasopressin-induced contraction of human coronary bypass graft internal mammary arteries. Both SR 49059 (1 μmol/l) and a peptide selective V1a antagonist {[d(CH2)5sarcosine7]arginine vasopressin} (1 μmol/l) abolished vasopressin-induced contraction. The non-peptide V1a receptor antagonist OPC-21268 (1 μmol/l) had no effect on vasopressin-induced contraction. 3. The effect of SR 49059 was specific to vascular vasopressin receptors as noradrenaline-induced contraction was not influenced by SR 49059. 4. The results of this study in vitro indicate that the non-peptide SR 49059 is a potent, specific vasopressin V1a receptor antagonist in the human internal mammary artery and suggest that it may be a useful tool for studying the pathophysiological role of vasopressin in man.


2007 ◽  
Vol 85 (5) ◽  
pp. 521-526 ◽  
Author(s):  
Ocal Berkan ◽  
Ihsan Bagcivan ◽  
Tijen Kaya ◽  
Kemal Yildirim ◽  
Sahin Yildirim ◽  
...  

The radial artery (RA) is used as a spastic coronary bypass graft. This study was designed to investigate the mechanism of vasorelaxant effects of YC-1 (3-(5′-hydroxymethyl-2′-furyl)-1-benzyl indazole), a nitric oxide (NO)-independent soluble guanylate cyclase (sGC) activator, and DEA/NO (diethylamine/nitric oxide), a NO-nucleophile adduct, on the human RA. RA segments (n = 25) were obtained from coronary artery bypass grafting patients and were divided into 3–4 mm vascular rings.Using the isolated tissue bath technique, the endothelium-independent vasodilatation function was tested in vitro by the addition of cumulative concentrations of YC-1 (10−10 to 3 × 10−7 mol/L) and DEA/NO (10−8 to 3 × 10−5 mol/L) following vasocontraction by phenylephrine in the presence or absence of 10−5 mol/L ODQ (1H-(1,2,4)oxadiazole(4,3-a)quinoxalin-1-one), the selective sGC inhibitor, 10−7 mol/L iberiotoxin, a blocker of Ca2+-activated K+ channels, or 10−5 mol/L ODQ plus 10−7 mol/L iberiotoxin. We also evaluated the effect of YC-1 and DEA/NO on the cGMP levels in vascular rings obtained from human radial artery (n = 6 for each drug). YC-1 (10−10 to 3 × 10−7 mol/L) and DEA/NO (10−8 to 3 × 10−5 mol/L) caused the concentration-dependent vasorelaxation in RA rings precontracted with phenylephrine (10−5 mol/L) (n = 20 for each drug). Pre-incubation of RA rings with ODQ, iberiotoxin, or ODQ plus iberiotoxin significantly inhibited the vasorelaxant effect of YC-1, but the inhibitor effect of ODQ plus iberiotoxin was significantly more than that of ODQ and iberiotoxin alone (p < 0.05). The vasorelaxant effect of DEA/NO almost completely abolished in the presence of ODQ and iberiotoxin plus ODQ, but did not significantly change in the presence of iberiotoxin alone (p > 0.05). The pEC50 value of DEA/NO was significantly lower than those for YC-1 (p < 0.01), with no change Emax values in RA rings. In addition, YC-1-stimulated RA rings showed more elevation in cGMP than that of DEA/NO (p < 0.05). These findings indicate that YC-1 is a more potent relaxant than DEA/NO in the human RA. The relaxant effects of YC-1 could be due to the stimulation of the sGC and Ca2+-sensitive K+channels, whereas the relaxant effects of DEA/NO could be completely due to the stimulation of the sGC. YC-1 and DEA/NO may be effective as vasodilator for the short-term treatment of perioperative spasm of coronary bypass grafts.


Sign in / Sign up

Export Citation Format

Share Document